Hypertrophic cardiomyopathy. Clinical spectrum and treatment

Circulation. 1995 Oct 1;92(7):1680-92. doi: 10.1161/01.cir.92.7.1680.

Abstract

HCM is a heterogeneous disease genotypically, phenotypically, pathophysiologically, clinically, and therapeutically. In decisions on the management of these patients, it is important to recognize this heterogeneity and to direct therapy at the predominant abnormalities.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Atrial Fibrillation / etiology
  • Calcium Channel Blockers / therapeutic use
  • Cardiomyopathy, Hypertrophic* / diagnosis
  • Cardiomyopathy, Hypertrophic* / genetics
  • Cardiomyopathy, Hypertrophic* / physiopathology
  • Cardiomyopathy, Hypertrophic* / therapy
  • Child
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Contraction / physiology
  • Myocardial Ischemia / physiopathology
  • Pacemaker, Artificial
  • Tachycardia, Ventricular / etiology
  • Ventricular Fibrillation / etiology
  • Ventricular Function, Left / physiology

Substances

  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers